Axon Enterprise, Inc $AXON Stock Holdings Lowered by Assetmark Inc.

Assetmark Inc. cut its position in Axon Enterprise, Inc (NASDAQ:AXON) by 21.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,699 shares of the biotechnology company’s stock after selling 2,349 shares during the quarter. Assetmark Inc.’s holdings in Axon Enterprise were worth $3,694,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AXON. Vanguard Group Inc. boosted its position in shares of Axon Enterprise by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after buying an additional 53,060 shares during the period. Geode Capital Management LLC increased its position in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after acquiring an additional 35,544 shares during the period. Baillie Gifford & Co. raised its stake in shares of Axon Enterprise by 1,198.7% during the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after purchasing an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC raised its position in shares of Axon Enterprise by 11.6% during the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after buying an additional 167,095 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after buying an additional 1,179,038 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

AXON has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday. Morgan Stanley set a $600.00 price objective on shares of Axon Enterprise in a research note on Thursday, May 7th. Piper Sandler raised their target price on shares of Axon Enterprise from $674.00 to $724.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Finally, Citizens Jmp restated a “market outperform” rating and set a $700.00 target price on shares of Axon Enterprise in a report on Thursday, June 25th. Fifteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $725.25.

Axon Enterprise Stock Performance

AXON stock opened at $491.49 on Thursday. The firm has a 50 day simple moving average of $478.98 and a 200 day simple moving average of $479.94. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $885.91. The stock has a market cap of $39.61 billion, a P/E ratio of 197.39, a P/E/G ratio of 10.43 and a beta of 1.38. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.90 million. During the same quarter in the prior year, the business earned $1.47 EPS. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. Research analysts anticipate that Axon Enterprise, Inc will post 1.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Patrick W. Smith sold 20,000 shares of Axon Enterprise stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $10,000,000.00. Following the completion of the sale, the chief executive officer owned 3,060,997 shares of the company’s stock, valued at approximately $1,530,498,500. This trade represents a 0.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CRO Cameron Brooks sold 1,242 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $500.00, for a total value of $621,000.00. Following the completion of the transaction, the executive owned 49,710 shares in the company, valued at $24,855,000. This trade represents a 2.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 58,989 shares of company stock valued at $30,527,983 in the last three months. Company insiders own 4.20% of the company’s stock.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: RBC Capital Markets said Axon appears poised for bookings growth in the second quarter, supported by multiple emerging drivers, which points to continued demand for its public safety technology. Axon Enterprise Poised for Bookings Growth With Multiple Emerging Drivers, RBC Capital Markets Says
• Positive Sentiment: Axon appointed two new independent directors with deep technology and artificial intelligence experience, which could strengthen oversight and support future product and platform strategy. Axon Enterprise (AXON) Appoints Two Directors With Deep Tech And AI Experience
• Neutral Sentiment: Axon announced it will report second-quarter 2026 earnings on August 5, putting the stock in a wait-and-see mode ahead of results and guidance. Axon to Release Second Quarter 2026 Earnings on August 5, 2026
• Neutral Sentiment: Recent coverage notes Axon is attracting trader attention, but the articles mainly reiterate the same core facts rather than adding a major new catalyst. Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: One valuation-focused article argued that Axon may be fully priced on a cash flow basis, even if it still screens as reasonable on sales multiples, reinforcing concerns that the stock’s recent run has left limited upside if growth cools. Axon (AXON) Stock Could Be Fully Priced On Cash Flow Yet A Bargain On Sales
• Negative Sentiment: Another note highlighted rising costs and pressure on margins, even though Axon is trying to offset them through efficiency initiatives and aims for better profitability later on. Can Axon Enterprise Improve Margin Performance Amid Rising Costs?

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.